Assessment of the associations between three VEGF polymorphisms and risk of prostate cancer.
Vascular endothelial growth factor (VEGF) plays a crucial role in the regulation of angiogenesis and is involved in the development and metastasis of common cancers. There were several case-controls studies published to assess the associations of VEGF polymorphisms with risk of prostate cancer, but the findings were inconsistent. We performed a meta-analysis to provide a comprehensive assessment of the associations of three VEGF polymorphisms with risk of prostate cancer. The pooled odds ratio (OR) with 95 % confidence interval (95 % CI) was calculated to assess the associations. Eleven individual case-control studies with a total of 5,209 cases of prostate cancer and 5,233 controls were finally included into our meta-analysis. Overall, VEGF rs833061 polymorphism was not associated with risk of prostate cancer (T versus C, OR?=?1.14, 95 % CI 0.91-1.44, P?=?0.26; TT versus CC, OR?=?1.09, 95 % CI 0.67-1.76, P?=?0.74; TT versus CC/CT: OR?=?1.46, 95 % CI 0.67-3.18, P?=?0.34; TT/CT versus CC, OR?=?1.08, 95 % CI 0.82-1.43, P?=?0.59). VEGF rs3025039 polymorphism was also not associated with risk of prostate cancer (T versus C, OR?=?1.03, 95 % CI 0.91-1.16, P?=?0.66; TT versus CC, OR?=?1.82 95 % CI 0.16-20.53, P?=?0.63; TT versus CC/CT, OR?=?2.00, 95 % CI 0.18-22.41, P?=?0.57; TT/CT versus CC, OR?=?0.72, 95 % CI 0.38-1.36, P?=?0.31). VEGF rs2010963 polymorphism was not associated with risk of prostate cancer under three models (C versus G, OR?=?1.17, 95 % CI 0.92-1.48, P?=?0.20; CC versus GG, OR?=?2.28, 95 % CI 0.90-5.75, P?=?0.08; CC versus GG/GC, OR?=?1.57, 95 % CI 0.67-3.68, P?=?0.30). In conclusison, current data suggest that those three VEGF polymorphisms are not obviously associated with risk of prostate cancer.